Literature DB >> 11749114

Epileptogenic brain malformations: clinical presentation, malformative patterns and indications for genetic testing.

R Guerrini1, R Carrozzo.   

Abstract

We review here those malformations of the cerebral cortex which are most often observed in epilepsy patients, for which a genetic basis has been elucidated or is suspected and give indications for genetic testing. There are three forms of lissencephaly (agyria-pachygyria) resulting from mutations of known genes, which can be distinguished because of their distinctive imaging features. They account for about 85% of all lissencephalies. Lissencephaly with posteriorly predominant gyral abnormality is caused by mutations of the LIS1 gene on chromosome 17. Anteriorly predominant lissencephaly in hemizygous males and subcortical band heterotopia (SBH) in heterozygous females are caused by mutations of the XLIS(or DCX) gene. Mutations of the coding region of XLIS were found in all reported pedigrees, and in most sporadic female patients with SBH. Missense mutations of both LIS1 and XLIS genes have been observed in some of the rare male patients with SBH. Autosomal recessive lissencephaly with cerebellar hypoplasia has been associated with mutations of the reelin gene. With few exceptions, children with lissencephaly have severe developmental delay and infantile spasms early in life. Patients with SBH have a mild to severe mental retardation with epilepsy of variable severity and type. X-linked bilateral periventricular nodular heterotopia (BPNH) consists of typical BPNH with focal epilepsy in females and prenatal lethality in males. About 88% of patients have focal epilepsy. Filamin A (FLNA) mutations have been reported in some families and in sporadic patients. Additional, possibly autosomal recessive gene(s) are likely to be involved in causing BPNH non-linked to FLN1. Tuberous sclerosis (TS) is a dominant disorder caused by mutations in at lest two genes, TSC1 and TSC2. 75% of cases are sporadic. Most patients with TS have epilepsy. Infantile spasms are a frequent early manifestation of TS. Schizencephaly (cleft brain) has a wide anatomo-clinical spectrum, including focal epilepsy in most patients. Familial occurrence is rare. Heterozygous mutations in the EMX2 gene have been reported in some patients. However, at present, there is no clear indication on the possible pattern of inheritance and on the practical usefulness that mutation detection in an individual with schizencephaly would carry in terms of genetic counselling. Amongst several syndromes featuring polymicrogyria, bilateral perisylvian polymicrogyria had familial occurrence on several occasions. Genetic heterogeneity is likely, including autosomal recessive, X-linked dominant, X-linked recessive inheritance and association to 22q11.2 deletions. FISH analysis for 22q11.2 is advisable in all patients with perisylvian polymicrogyria. Parents of an affected child with normal karyotype should be given up to a 25% recurrence risk. Copyright 2001 BEA Trading Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11749114     DOI: 10.1053/seiz.2001.0650

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  10 in total

Review 1.  Genetics of epilepsy.

Authors:  Dimitri M Kullmann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

2.  Polymicrogyria: correlation of magnetic resonance imaging and clinical findings.

Authors:  Ertugrul Mavili; Abdulhakim Coskun; Huseyin Per; Halil Donmez; Sefer Kumandas; Ali Yikilmaz
Journal:  Childs Nerv Syst       Date:  2012-06       Impact factor: 1.475

Review 3.  Genetic malformations of cortical development.

Authors:  Renzo Guerrini; Carla Marini
Journal:  Exp Brain Res       Date:  2006-05-25       Impact factor: 1.972

4.  Ehlers-Danlos syndrome and periventricular nodular heterotopia in a Spanish family with a single FLNA mutation.

Authors:  P Gómez-Garre; M Seijo; E Gutiérrez-Delicado; M Castro del Río; C de la Torre; C Gómez-Abad; J Morales-Corraliza; M Puig; J M Serratosa
Journal:  J Med Genet       Date:  2005-07-01       Impact factor: 6.318

5.  Van Maldergem syndrome: further characterisation and evidence for neuronal migration abnormalities and autosomal recessive inheritance.

Authors:  Sahar Mansour; Marielle Swinkels; Paulien A Terhal; Louise C Wilson; Philip Rich; Lionel Van Maldergem; Petra J G Zwijnenburg; Christine M Hall; Stephen P Robertson; Ruth Newbury-Ecob
Journal:  Eur J Hum Genet       Date:  2012-04-04       Impact factor: 4.246

Review 6.  Monitoring and Managing Patients with Tuberous Sclerosis Complex: Current State of Knowledge.

Authors:  Inês Gomes; Joana Jesus Ribeiro; Filipe Palavra
Journal:  J Multidiscip Healthc       Date:  2022-07-14

Review 7.  Epileptic syndromes: From clinic to genetic.

Authors:  Abbas Tafakhori; Vajiheh Aghamollaii; Sara Faghihi-Kashani; Payam Sarraf; Laleh Habibi
Journal:  Iran J Neurol       Date:  2015-01-05

8.  Functional Connectivity and Genetic Profile of a "Double-Cortex"-Like Malformation.

Authors:  Giulia Sprugnoli; Giampaolo Vatti; Simone Rossi; Alfonso Cerase; Alessandra Renieri; Maria A Mencarelli; Federico Zara; Alessandro Rossi; Emiliano Santarnecchi
Journal:  Front Integr Neurosci       Date:  2018-06-12

9.  Altered excitatory and inhibitory neocortical circuitry leads to increased convulsive severity after pentylenetetrazol injection in an animal model of schizencephaly, but not of microgyria.

Authors:  Luiza Dos Santos Heringer; Julia Rios Carvalho; Julia Teixeira Oliveira; Bruna Texeira Silva; Domethila Mariano de Souza Aguiar Dos Santos; Anna Lecticia Martinez Martinez Toledo; Laura Maria Borges Savoldi; Debora Magalhães Portela; Suelen Adriani Marques; Paula Campello Costa Lopes; Ana Maria Blanco Martinez; Henrique Rocha Mendonça
Journal:  Epilepsia Open       Date:  2022-07-21

10.  Bilateral frontoparietal polymicrogyria, Lennox-Gastaut syndrome, and GPR56 gene mutations.

Authors:  Elena Parrini; Anna Rita Ferrari; Thomas Dorn; Christopher A Walsh; Renzo Guerrini
Journal:  Epilepsia       Date:  2008-10-06       Impact factor: 5.864

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.